Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind,...

Related Keywords

France ,Dublin ,Ireland ,Japan ,United States ,Japanese ,American ,Dauvilliersy Arnulf ,Kristin Bhavnani ,Andrean Flynn ,Rob Iannone ,Yves Dauvilliers ,American Psychiatric Association ,Jazz Pharmaceuticals Inc ,International Classification Of Sleep Disorders ,Department Of Neurology ,Jazz Pharmaceuticals ,Drug Administration ,Head Of Global Corporate Affairs ,United States Drug Enforcement Agency ,Office Of Orphan Product Development ,Us Drug Enforcement Agency ,Nasdaq ,American Academy Of Sleep Medicine ,Health Problem ,Prnewswire Jazz Pharmaceuticals ,Wake Disorders Centre ,Epworth Sleepiness Scale ,Idiopathic Hypersomnia Severity Scale ,Gui De Chauliac Hospital ,Orphan Drug Exclusivity ,Orphan Drug Designation ,Patient Global Impression ,Clinical Global Impression ,Functional Outcomes ,Sleep Questionnaire ,Work Productivity ,Activity Impairment Questionnaire ,Specific Health Problem ,Boxed Warning ,Prescribing Information ,Medication Guide ,Orphan Product Development ,Enforcement Agency ,Global Corporate Affairs ,Palo Alto ,International Classification ,Third Edition ,Idiopathic Hypersomnia Severity ,States Drug Enforcement ,Accessed December ,Statistical Manual ,Fifth Edition ,Opin Investig ,Jazz Pharmaceuticals Plc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,